Fluticasone Propionate And Salmeterol Powder, Metered
Product Images NDC 50090-3271

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 50090-3271). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fp Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 1)

FDA Label Image

Figure 8 (Fluticasone Propionate Salmeterol Inhalation Powde 10)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 11)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 12)

FDA Label Image

Figurr A (Fluticasone Propionate Salmeterol Inhalation Powde 13)

This text appears to refer to an inhaler with a dose counter, a vent, a mouthpiece, and a yellow cap. Further information or context is not available.*

FDA Label Image

Figure B (Fluticasone Propionate Salmeterol Inhalation Powde 14)

This is a description of an inhaler that has 60 doses when full and zero doses when empty.*

FDA Label Image

Figure C (Fluticasone Propionate Salmeterol Inhalation Powde 15)

FDA Label Image

Figure D (Fluticasone Propionate Salmeterol Inhalation Powde 16)

FDA Label Image

Breathe Out Image (Fluticasone Propionate Salmeterol Inhalation Powde 17)

FDA Label Image

Figure F (Fluticasone Propionate Salmeterol Inhalation Powde 18)

FDA Label Image

Figure G (Fluticasone Propionate Salmeterol Inhalation Powde 19)

FDA Label Image

Salmeterol Chem Structure (Fluticasone Propionate Salmeterol Inhalation Powde 2)

FDA Label Image

Figure H (Fluticasone Propionate Salmeterol Inhalation Powde 20)

FDA Label Image

Teva Logo (Fluticasone Propionate Salmeterol Inhalation Powde 21)

FDA Label Image

Figure 1 (Fluticasone Propionate Salmeterol Inhalation Powde 3)

FDA Label Image

Figure 2 (Fluticasone Propionate Salmeterol Inhalation Powde 4)

FDA Label Image

Figure 3 (Fluticasone Propionate Salmeterol Inhalation Powde 5)

FDA Label Image

Figure 4 (Fluticasone Propionate Salmeterol Inhalation Powde 6)

This text represents a table that includes the names of different medications, their doses, and sample sizes (N) of patients who received them. It also presents the mean change in FEV (forced expiratory volume) in liters measured at different time intervals (baseline, 1 hour, day 1, and 2-11 days) after the medication was taken. There is insufficient information to provide a complete description or information about the purpose of the study.*

FDA Label Image

Figure 5 (Fluticasone Propionate Salmeterol Inhalation Powde 7)

FDA Label Image

Figure 6 (Fluticasone Propionate Salmeterol Inhalation Powde 8)

FDA Label Image

Figure 7 (Fluticasone Propionate Salmeterol Inhalation Powde 9)

This is a table showing the mean change in FEV (forced expiratory volume) in liters for different treatments and placebos. The treatments include FSMDPI 232 meg/14 mcg, FSMDPI 113 mcg/14 meg, MDPI 232 meg, and MDPI 113 meg. The placebo group is also included in the study. The table provides the number of participants for each group and shows the mean changes in FEV over time, with data collected on Day 1 and hourly thereafter.*

FDA Label Image

Lbl500903271

FDA Label Image

Lbl500903272

FDA Label Image

Label Image (Lbl500903387)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.